$BDPT
BIOADAPTIVES, INC.

2023 Q4 Form 10-Q Financial Statement

#000164033423002105 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $7.200K $15.65K
YoY Change 80.9% 368.95%
Cost Of Revenue $4.500K $11.00K
YoY Change 52.54% 722.66%
Gross Profit $2.700K $4.650K
YoY Change 162.14% 132.5%
Gross Profit Margin 37.5% 29.71%
Selling, General & Admin $75.30K $59.22K
YoY Change 172.33% -20.58%
% of Gross Profit 2788.89% 1273.55%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization -$10.82K $37.64K
YoY Change -1668.12% 742.06%
% of Gross Profit -400.74% 809.46%
Operating Expenses $64.48K $96.86K
YoY Change 127.52% 22.54%
Operating Profit -$61.78K -$92.21K
YoY Change 126.22% 19.69%
Interest Expense -$355.0K $20.63K
YoY Change 36126.53% -78.08%
% of Operating Profit
Other Income/Expense, Net $79.15K
YoY Change -139.72%
Pretax Income -$268.3K -$13.06K
YoY Change 848.73% -95.27%
Income Tax
% Of Pretax Income
Net Earnings -$268.3K -$13.06K
YoY Change 848.73% -95.27%
Net Earnings / Revenue -3726.39% -83.46%
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 776.5M shares 776.5M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $60.78K $152.1K
YoY Change 138.82% 747.71%
Cash & Equivalents $60.78K $152.1K
Short-Term Investments $0.00 $10.00
Other Short-Term Assets $12.50K
YoY Change
Inventory $15.28K $7.250K
Prepaid Expenses $10.00K
Receivables $3.340K
Other Receivables $0.00
Total Short-Term Assets $88.56K $162.7K
YoY Change 158.01% 527.1%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles $15.17K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $15.44K $166.6K
YoY Change 416.39% 4435.25%
TOTAL ASSETS
Total Short-Term Assets $88.56K $162.7K
Total Long-Term Assets $15.44K $166.6K
Total Assets $104.0K $329.3K
YoY Change 178.72% 1011.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $443.6K $3.344K
YoY Change 6292.56% -37.38%
Accrued Expenses $138.0K $126.3K
YoY Change 13491.63% 4716.7%
Deferred Revenue
YoY Change
Short-Term Debt $329.2K $333.2K
YoY Change -16.03% -23.25%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.751M $1.475M
YoY Change 17.59% -9.25%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.751M $1.475M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $1.751M $1.475M
YoY Change 17.59% -9.25%
SHAREHOLDERS EQUITY
Retained Earnings -$8.264M -$7.996M
YoY Change 9.43% 6.28%
Common Stock $89.58K $77.65K
YoY Change 254.69% 484.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.647M -$1.146M
YoY Change
Total Liabilities & Shareholders Equity $104.0K $329.3K
YoY Change 178.72% 1011.94%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$268.3K -$13.06K
YoY Change 848.73% -95.27%
Depreciation, Depletion And Amortization -$10.82K $37.64K
YoY Change -1668.12% 742.06%
Cash From Operating Activities -$91.29K -$56.15K
YoY Change 231.96% -15.7%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 168.1K
YoY Change -100.0% 380.29%
NET CHANGE
Cash From Operating Activities -91.29K -56.15K
Cash From Investing Activities
Cash From Financing Activities 0.000 168.1K
Net Change In Cash -91.29K 111.9K
YoY Change -1317.2% -454.16%
FREE CASH FLOW
Cash From Operating Activities -$91.29K -$56.15K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
776474023 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
252554765 shares
CY2023Q3 bdpt Common Stock Capital Shares Reserved For Future Issuance1
CommonStockCapitalSharesReservedForFutureIssuance1
10000 shares
dei Entity Central Index Key
EntityCentralIndexKey
0001575142
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1250000000 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
776474023 shares
CY2022Q4 bdpt Common Stock Capital Shares Reserved For Future Issuance1
CommonStockCapitalSharesReservedForFutureIssuance1
10000 shares
us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate
0 pure
CY2022 us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate
0 pure
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Entity File Number
EntityFileNumber
000-54949
dei Entity Registrant Name
EntityRegistrantName
BioAdaptives Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-2592228
dei Entity Address Address Line1
EntityAddressAddressLine1
2620 Regatta Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 102
dei Entity Address City Or Town
EntityAddressCityOrTown
Las Vegas
dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89128
dei City Area Code
CityAreaCode
702
dei Local Phone Number
LocalPhoneNumber
659-8829
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
776464023 shares
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
152072 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25405 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3344 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
0 usd
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
11 usd
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
42 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
7250 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
8877 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
162677 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
34324 usd
CY2023Q3 us-gaap Indefinite Lived License Agreements
IndefiniteLivedLicenseAgreements
166625 usd
CY2022Q4 us-gaap Indefinite Lived License Agreements
IndefiniteLivedLicenseAgreements
2990 usd
CY2023Q3 us-gaap Assets
Assets
329302 usd
CY2022Q4 us-gaap Assets
Assets
37314 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
433375 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
409920 usd
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
708584 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
686856 usd
CY2023Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
79829 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
7647 usd
CY2023Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
325671 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
381793 usd
CY2023Q3 bdpt Notes Payable Related Parties Classified As Current
NotesPayableRelatedPartiesClassifiedAsCurrent
7520 usd
CY2022Q4 bdpt Notes Payable Related Parties Classified As Current
NotesPayableRelatedPartiesClassifiedAsCurrent
10246 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1475150 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1488815 usd
CY2023Q3 us-gaap Liabilities
Liabilities
1475150 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1488815 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1250000000 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
77647 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
25255 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
6771839 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
6074763 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7995844 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7551679 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1145848 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1451501 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
329302 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
37314 usd
CY2023Q3 us-gaap Revenues
Revenues
15649 usd
CY2022Q3 us-gaap Revenues
Revenues
3337 usd
us-gaap Revenues
Revenues
21364 usd
us-gaap Revenues
Revenues
13192 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
10999 usd
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
1337 usd
us-gaap Cost Of Revenue
CostOfRevenue
13244 usd
us-gaap Cost Of Revenue
CostOfRevenue
7096 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
4650 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
2000 usd
us-gaap Gross Profit
GrossProfit
8120 usd
us-gaap Gross Profit
GrossProfit
6096 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
33706 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
43981 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
60258 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
236698 usd
CY2023Q3 us-gaap Professional Fees
ProfessionalFees
25514 usd
CY2022Q3 us-gaap Professional Fees
ProfessionalFees
30588 usd
us-gaap Professional Fees
ProfessionalFees
76010 usd
us-gaap Professional Fees
ProfessionalFees
102532 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
37643 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4476 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
38989 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
61464 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
96863 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
79045 usd
us-gaap Operating Expenses
OperatingExpenses
175257 usd
us-gaap Operating Expenses
OperatingExpenses
400694 usd
CY2023Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-11 usd
CY2022Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-31 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-31 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-158 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
20625 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
94106 usd
us-gaap Interest Expense
InterestExpense
123941 usd
us-gaap Interest Expense
InterestExpense
199572 usd
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
261488 usd
CY2022Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-105143 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
8644 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-272965 usd
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-161700 usd
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-161700 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
79152 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-199280 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-277028 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-472695 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-13061 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-276325 usd
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-444165 usd
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-867293 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13061 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-276325 usd
us-gaap Net Income Loss
NetIncomeLoss
-444165 usd
us-gaap Net Income Loss
NetIncomeLoss
-867293 usd
CY2023Q3 bdpt Basic And Diluted Earning Per Share
BasicAndDilutedEarningPerShare
-0.00
CY2022Q3 bdpt Basic And Diluted Earning Per Share
BasicAndDilutedEarningPerShare
-0.00
bdpt Basic And Diluted Earning Per Share
BasicAndDilutedEarningPerShare
-0.00
bdpt Basic And Diluted Earning Per Share
BasicAndDilutedEarningPerShare
-0.01
CY2023Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
730006523 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
89333996 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
482799498 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
77615330 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1451501 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
108036 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-287187 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1630652 usd
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
96057 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-143917 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1678512 usd
CY2023Q3 bdpt Series A Preferred Stock Issued For License Fee Amount
SeriesAPreferredStockIssuedForLicenseFeeAmount
22625 usd
CY2023Q3 bdpt Series B Preferred Stock Issued For Settlement Of Debt Related Party Amount
SeriesBPreferredStockIssuedForSettlementOfDebtRelatedPartyAmount
165000 usd
CY2023Q3 bdpt Series B Preferred Stock Issued For License Fee Amount
SeriesBPreferredStockIssuedForLicenseFeeAmount
180000 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
178100 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13061 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1145848 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-1093039 usd
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
52017 usd
CY2022Q1 bdpt Debts Forgiveness Related Party
DebtsForgivenessRelatedParty
10000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-367131 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-1398153 usd
CY2022Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
121615 usd
CY2022Q2 us-gaap Standard Product Warranty Accrual Additions From Business Acquisition
StandardProductWarrantyAccrualAdditionsFromBusinessAcquisition
5429 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-223837 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-1494946 usd
CY2022Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
175413 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-276325 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1595858 usd
us-gaap Profit Loss
ProfitLoss
-444165 usd
us-gaap Profit Loss
ProfitLoss
-867293 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-8644 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
272965 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
38989 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
61464 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
92318 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
161221 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-161700 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-31 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-158 usd
us-gaap Accounts Receivable Sale
AccountsReceivableSale
3344 usd
us-gaap Accounts Receivable Sale
AccountsReceivableSale
0 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1627 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-3250 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
29481 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
172177 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-470 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
1803 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-132477 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-199755 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
178100 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1623 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
51044 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1623 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
50000 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
1623 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
25272 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
80000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
160000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
259144 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
136351 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
126667 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-63404 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25405 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82936 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
152072 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19532 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
0 usd
us-gaap Interest Paid Net
InterestPaidNet
4728 usd
us-gaap Separate Account Liability Period Increase Decrease
SeparateAccountLiabilityPeriodIncreaseDecrease
150000 usd
us-gaap Separate Account Liability Period Increase Decrease
SeparateAccountLiabilityPeriodIncreaseDecrease
142000 usd
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
204093 usd
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
349045 usd
bdpt Issuance Series A Preferred Stock For License Fee
IssuanceSeriesAPreferredStockForLicenseFee
22625 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
180000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
165000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
bdpt Debts Forgiveness Related Party
DebtsForgivenessRelatedParty
10000 usd
us-gaap Standard Product Warranty Accrual Additions From Business Acquisition
StandardProductWarrantyAccrualAdditionsFromBusinessAcquisition
5429 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The preparation of consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company, and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p>
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
11 usd
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
708584 usd
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
42 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
686856 usd
CY2023Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
325671 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
381793 usd
bdpt Value Assigned Of Derivatives Liabilities
ValueAssignedOfDerivativesLiabilities
728213 usd
bdpt Debt Discount
DebtDiscount
150000 usd
bdpt Derivative Loss On Derivative1
DerivativeLossOnDerivative1
578213 usd
bdpt Addition Of New Derivatives Recognized As Debt Discounts
AdditionOfNewDerivativesRecognizedAsDebtDiscounts
150000 usd
bdpt Addition Of New Derivatives Recognized As Loss On Derivatives
AdditionOfNewDerivativesRecognizedAsLossOnDerivatives
578213 usd
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1250000000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
252544765 shares
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
323919258 shares
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
204093 usd
us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1
P2Y
bdpt Term Of Licenses Range Description
TermOfLicensesRangeDescription
The term of licenses is a range from 1 to 3 years for the certain products
bdpt Amortization Expense
AmortizationExpense
38989 usd

Files In Submission

Name View Source Status
bdpt-20230930_def.xml Edgar Link unprocessable
bdpt-20230930_lab.xml Edgar Link unprocessable
0001640334-23-002105-index-headers.html Edgar Link pending
0001640334-23-002105-index.html Edgar Link pending
0001640334-23-002105.txt Edgar Link pending
0001640334-23-002105-xbrl.zip Edgar Link pending
bdpt-20230930.xsd Edgar Link pending
bdpt_10q.htm Edgar Link pending
bdpt_10qimg3.jpg Edgar Link pending
bdpt_ex311.htm Edgar Link pending
bdpt_ex312.htm Edgar Link pending
bdpt_ex321.htm Edgar Link pending
bdpt_ex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
bdpt-20230930_cal.xml Edgar Link unprocessable
bdpt-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bdpt_10q_htm.xml Edgar Link completed
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending